PNPLA3 rs738409 polymorphism associated with hepatic steatosis and advanced fibrosis in patients with chronic hepatitis C virus: A meta-analysis

Gut and Liver

Volumn 10, Issue 3, 2016, Pages 456-463

  Fan, Jia Hao ^a   Xiang, Ming Que ^b   Li, Qing Ling ^a   Shi, Hong Tao ^a   Guo, Jin Jun ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b Ninth People's Hospital of Chongqing   (China)

Author keywords

Advanced liver fibrosis; Chronic; Fatty liver; Hepatitis C; Meta analysis; Patatin like phospholipase domain containing protein 3 rs738409

Indexed keywords

PATATIN LIKE PHOSPHOLIPASE DOMAIN CONTAINING PROTEIN 3; PEPTIDES AND PROTEINS; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ARTICLE; ASIAN; CAUCASIAN; CHRONIC LIVER DISEASE; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; HEPATITIS C VIRUS; HUMAN; LIVER FIBROSIS; PNPLA3 GENE; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN CONTINENTAL ANCESTRY GROUP; CHRONIC HEPATITIS C; GENETICS; LIVER CIRRHOSIS; META ANALYSIS;

ASIAN CONTINENTAL ANCESTRY GROUP; EUROPEAN CONTINENTAL ANCESTRY GROUP; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; LIPASE; LIVER CIRRHOSIS; MEMBRANE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84969188137     PISSN: 19762283     EISSN: None     Source Type: Journal    
DOI: 10.5009/gnl15261     Document Type: Article

References (34)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-567
2. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver Int 2009;29 Suppl 1:89-99
3. Niederau C, Lange S, Heintges T, et al. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:1687-1695
4. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009;51:655-666
5. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-521.e6
6. Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636-1642
7. Missiha SB, Ostrowski M, Heathcote EJ. Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 2008;134:1699-1714
8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832
9. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003;52:574-579
10. Stattermayer AF, Rutter K, Beinhardt S, et al. Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. J Hepatol 2012;57:492-498
11. Valenti L, Aghemo A, Stattermayer AF, et al. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin. Aliment Pharmacol Ther 2012;35: 1434-1442
12. Stattermayer AF, Rutter K, Beinhardt S, et al. Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. Liver Int 2014;34:388-395
13. Miyashita M, Ito T, Sakaki M, et al. Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C. J Viral Hepat 2012;19:608-614
14. Trepo E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology 2011;54:60-69
15. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in metaanalyses. Eur J Epidemiol 2010;25:603-605
16. Valenti L, Nobili V, Al-Serri A, et al. The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. J Hepatol 2011;55:1409-1414
17. Jackson D, White IR, Riley RD. Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 2012;31:3805-3820
18. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA 2006;295:676-680
19. Zintzaras E, Ioannidis JP. HEGESMA: genome search meta-analysis and heterogeneity testing. Bioinformatics 2005;21:3672-3673
20. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008;40:1461-1465
21. Rotman Y, Koh C, Zmuda JM, Kleiner DE, Liang TJ, Nash CR. The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894-903
22. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010;51:1209-1217
23. Stickel F, Buch S, Lau K, et al. Genetic variation in the PNPLA3 gene is associated with alcoholic liver injury in Caucasians. Hepatology 2011;53:86-95
24. Tian C, Stokowski RP, Kershenobich D, Ballinger DG, Hinds DA. Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 2010;42:21-23
25. Trepo E, Gustot T, Degre D, et al. Common polymorphism in the PNPLA3/adiponutrin gene confers higher risk of cirrhosis and liver damage in alcoholic liver disease. J Hepatol 2011;55:906-912
26. Chung KC, Burns PB, Kim HM. A practical guide to meta-analysis. J Hand Surg Am 2006;31:1671-1678
27. Dennis J, Hawken S, Krewski D, et al. Bias in the case-only design applied to studies of gene-environment and gene-gene interaction: a systematic review and meta-analysis. Int J Epidemiol 2011;40: 1329-1341
28. Rosenthal R, DiMatteo MR. Meta-analysis: recent developments in quantitative methods for literature reviews. Annu Rev Psychol 2001;52:59-82
29. Agundez JA, Garcia-Martin E, Maestro ML, et al. Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease. PLoS One 2012;7:e37998
30. Valenti L, Aghemo A, Stattermayer AF. Interaction between IL28B and PNPLA3 genotypes in the pathogenesis of steatosis in chronic hepatitis C non genotype-3 patients. J Hepatol 2012;56:1209-1210
31. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010;139:1865-1876
32. Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461: 798-801
33. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014;59:318-327
34. Thakkinstian A, McElduff P, D'Este C, Duffy D, Attia J. A method for meta-analysis of molecular association studies. Stat Med 2005; 24:1291-1306